Advances in psychopharmacology promised various safe, evidence-based treatment options for older adults with mental health and cognitive disorders. Benzodiazepines replaced barbiturates, atypical antipsychotics would make conventional agents obsolete, and new antidepressant classes, such as the selective serotonin reuptake inhibitors, would take over from the tricyclic antidepressants and monoamine oxidase inhibitors. While each of these new classes have offered significant treatment benefits—typically because of fewer adverse effects—the recognized risks for each has steadily grown the longer the newer class is used.
Iaboni A, Maust DT. A Status Update on the Association Between Antidepressants and Fractures: Breaking Up? JAMA Psychiatry. 2019;76(2):113–114. doi:10.1001/jamapsychiatry.2018.3632
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: